Tissue Regenix Group PLC (LON:TRX) has started the first phase of its planned manufacturing capacity expansion programme in San Antonio, Texas.
The regenerative medical devices company said the capacity expansion represents a key element of its commercial development plan.
The first part of the multi-phase expansion programme is expected to take about six months to complete and will include the development of operational capabilities in the new 21,000 square feet building to house freezers and distribution functions that will free up space for additional sterile packaging clean rooms to be built in the existing facility.
Tissue Regenix said its board is also evaluating the possibility of combining some elements of the later phases into this initial work in order to minimise future potential disruption and the overall costs associated with the expansion programme.
Meanwhile, demand for the group's products, in particular the BioRinse orthopaedic product portfolio, continues to grow and the first expansion phase will allow for an increase of roughly 50% to the group's current BioRinse processing capacity.
“Not only do we expect this investment to provide the additional capacity required to efficiently scale our business and drive further commercial growth, it will also increase the number of patients who can benefit from our broadening product portfolio,” Gareth Jones, the interim chief executive officer of Tissue Regenix in a statement.